Adoption rates of recommended vaccines and influencing factors among patients with inflammatory arthritis: a patient survey

Moraliyska, Rosina; Georgiev, Tsvetoslav; Bogdanova-Petrova, Simona; Shivacheva, Tanya

doi:10.1007/s00296-023-05476-2

Cited by 6 publications

(4 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These findings are of extreme concern and are significantly lower than the values of 77% for seasonal influenza among Irish patients receiving immunoglobulin replacement therapy [ 25 ] and of 41% for pneumococcal vaccination among patients with chronic conditions in France [ 26 ]. Similar values of uptake have been observed for pneumococcal and influenza vaccinations with only 13.9% and 1.5% among patients with inflammatory arthritis in Bulgaria [ 27 ], 7.8% of diabetic patients in China [ 28 ], and 7% of chronic obstructive pulmonary disease patients who have received the influenza vaccine in Saudi Arabia [ 29 ]; in China, 3.29% and 6.69% of chronic disease patients aged < 65 years and ≥65 years have received the pneumococcal vaccine [ 30 ]. The multinomial logistic regression analysis showed that a higher number of comorbidities increased the likelihood of having received vaccinations, as confirmed in other studies [ 31 , 32 ].…”

Section: Discussionsupporting

confidence: 75%

Knowledge, Attitudes, and Coverage of Recommended Vaccinations in Individuals with Chronic Medical Conditions: A Cross-Sectional Telephone Survey in Italy

Sansone,

Miraglia del Giudice,

Della Polla

et al. 2024

Vaccines

View full text Add to dashboard Cite

Background: This cross-sectional survey investigated the knowledge, attitudes, and coverage of recommended vaccinations among a random sample of patients with chronic medical conditions, at higher risk of vaccine-preventable diseases (VPDs), in Italy. Methods: The survey was conducted via telephone-based interviews. Results: Multinomial regression analysis showed that the patients who believed that VPDs were severe were more likely to know one recommended vaccination; those who believed that VPDs were severe and those who were advised from a general practitioner (GP) were more likely to know two vaccinations; those who were older, graduated, with more time from diagnosis, who believed that VPDs were severe, who did not need additional information, and who were advised from a GP were more likely to know three or four vaccinations. Patients who knew at least one vaccination, who perceived themselves at risk, and who were advised from a GP were more likely to have received one vaccination; those who knew more than one vaccination and who were advised from a GP were more likely to receive two or three vaccinations. Among the unvaccinated, patients who were unmarried/not cohabiting, those who needed information, and who believed that vaccinations were useful and safe were more willing to receive the recommended vaccinations. Conclusions: Educational interventions are needed to improve the adherence of individuals with chronic medical conditions.

show abstract

Section: Discussionsupporting

confidence: 75%

Knowledge, Attitudes, and Coverage of Recommended Vaccinations in Individuals with Chronic Medical Conditions: A Cross-Sectional Telephone Survey in Italy

Sansone,

Miraglia del Giudice,

Della Polla

et al. 2024

Vaccines

View full text Add to dashboard Cite

show abstract

“…The low vaccination rate among AIIRD patients found in our study is not surprising in this context but fits into the available literature data. The vaccination rate among AIIRD patients varies between different countries and is between 1.5 and 92.4% for influenza vaccines [6,7,, 5.8 and 71.2% for the pneumococcal vaccine [13,[15][16][17][18][20][21][22][23][24][25][26][27][28][29][30][31][32][33][34]37,38,[41][42][43][44][45][46], 24.3 and 83.7% for tetanus vaccination (booster within 10 years) [26,27,29,33,41,42], and 35.8 and 98.1% for the COVID-19 vaccine (following the recommendations applicable at the time of this study) [6,[40][41][42][43][47][48][49]. An additional problem is the fact that vaccination coverage in Polish AIIRD patients is comparably low as in the general Polish population, even though AIIRD patients constitute a group of particular ...…”

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Do Not Leave Your Patients in the Dark—Using American College of Rheumatology and European Alliance of Associations for Rheumatology Recommendations for Vaccination in Polish Adult Patients with Autoimmune Inflammatory Rheumatic Diseases

Wroński,

Palej,

Stańczyk

et al. 2023

Vaccines

View full text Add to dashboard Cite

(1) Introduction: Patients with autoimmune inflammatory rheumatic diseases (AIIRD) face a higher infectious risk compared to the general population. As per the ACR and EULAR recommendations, vaccinations against influenza, COVID-19, pneumococci, and tetanus are recommended for most patients with AIIRD. (2) Objectives: This study aimed to assess vaccination coverage among Polish AIIRD patients and identify factors influencing it. (3) Patients and Methods: This study was conducted at the reference rheumatological center in Poland between May 2023 and October 2023. The study participants completed a questionnaire covering their knowledge of vaccination recommendations, actual vaccination status, factors affecting their decision to vaccinate, and their perspectives on immunization. (4) Results: This study involved 300 AIIRD patients and 60 controls. Both groups exhibited comparably low vaccination rates for all diseases (the highest for COVID-19—52% in both groups and the lowest for pneumococci—7.7% and 10%, respectively). Knowledge about recommended vaccinations was limited among patients in both groups. AIIRD patients were also not aware that they should avoid live vaccines. The primary motivators for vaccination among AIIRD patients were fear of infection (up to 75%) and medical advice (up to 74.6%). Conversely, the predominant reasons for non-vaccination were a lack of knowledge that vaccination is recommended (up to 74.7%) and concerns about potential adverse effects (up to 48.6%). Many patients reported not receiving vaccination recommendations from either primary care physicians or rheumatologists. (5) Conclusions: To enhance vaccination coverage among AIIRD patients in Poland, it is essential to educate them about vaccinations during routine medical consultations, emphasizing the increased risk of infection, informing them about recommended vaccinations, and clarifying doubts about adverse effects.

show abstract

“…In order to promote vaccination uptake and improve awareness of patients, new plans and strategies are strongly needed. The aims of these plans are the explanation of the patient's autoimmune status and emphasizing the safety and efficacy of vaccines [3].…”

Section: Introductionmentioning

confidence: 99%

Acceptance, tolerability, and effect of COVID-19 vaccination on disease activity in a cohort of Egyptian systemic lupus erythematosus patients: Real-life experience

Abu-Zaid,

Aly,

Moshrif

et al. 2023

RBJ

View full text Add to dashboard Cite

Abstract Objective: To assess the tolerance and effects of COVID-19 vaccination in Egyptian patients with systemic lupus erythematosus (SLE), such as incident flare risk, based on the patient’s perspective. Methods: SLE patients were included in this multicenter cross-sectional questionnaire-based analysis. Data included demographic and clinical features, prior COVID-19 infection, vaccine acceptability, type of vaccination, disease status before and after vaccination, and related side effects. Results: The total number of patients included was 230. Ages ranged from 18 to 64 years, disease duration from 1 to 15 years, and 92.6% were females. Only 31.7% of the study population were COVID-infected; most (70.7%) were treated at home, while 1.2% needed ICU. In contrast, 53% of our patients were vaccinated, and 47% were not vaccinated, primarily due to fear of side effects or disease flare. After the first dose of vaccination, 44.1% reported vaccine-related side effects, of which fatigue, fever, myalgia, as well as injection site reaction were the prevalent complications. The highest incidence of side effects was in AstraZeneca (78%), while the least was in Sinopharm (29.6%). 16.3% of vaccinated patients were COVID infected after vaccination, and 88.2% were treated at home. Only 14.6% of the vaccinated population experienced a lupus flare, primarily after the first dose, with no significant difference between the type of vaccine and lupus flares. Conclusion: The acceptance of COVID-19 vaccination among our lupus patients was neutral. The observed adverse effects were comparable to those reported by healthy individuals. Post-vaccination lupus flares were infrequent and unrelated to the vaccine type but rather to the pre-vaccination disease activity state. Keywords: Lupus, COVID, Vaccine, Flare

show abstract

Adoption rates of recommended vaccines and influencing factors among patients with inflammatory arthritis: a patient survey

Cited by 6 publications

References 29 publications

Knowledge, Attitudes, and Coverage of Recommended Vaccinations in Individuals with Chronic Medical Conditions: A Cross-Sectional Telephone Survey in Italy

Knowledge, Attitudes, and Coverage of Recommended Vaccinations in Individuals with Chronic Medical Conditions: A Cross-Sectional Telephone Survey in Italy

Do Not Leave Your Patients in the Dark—Using American College of Rheumatology and European Alliance of Associations for Rheumatology Recommendations for Vaccination in Polish Adult Patients with Autoimmune Inflammatory Rheumatic Diseases

Acceptance, tolerability, and effect of COVID-19 vaccination on disease activity in a cohort of Egyptian systemic lupus erythematosus patients: Real-life experience

Contact Info

Product

Resources

About